AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|
26.9 C
New York
Saturday, June 20, 2026

Tag: exchange

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Bronstein, Gewirtz & Grossman LLC Urges SES AI Corporation Investors to Act: Class Action Filed Alleging Investor Harm

New class action for SES AI (SES) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/26/2026

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Tradr to Ring Opening Bell at Cboe to Celebrate SpaceX ETF Launches

Tradr ETFs will ring Cboe's Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and...

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SES AI Corporation (NYSE: SES) between January 29, 2025 and March 4, 2026, both dates inclusive (the “Class Period”), of the important June 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Defiance ETFs 宣布 Defiance Daily 2X Space ETF (SPCL) 在 Cboe BZX Exchange, Inc. 暂停交易

迈阿密, June 14, 2026 (GLOBE NEWSWIRE) -- 主题型及杠杆型交易所交易基金领域的领军者 Defiance ETFs 今日宣布,Defiance Daily 2X Space ETF (Cboe BZX 交易所代码:SPCL) 份额的交易已被 Cboe BZX Exchange, Inc.(简称“交易所”)临时暂停。

Defiance ETFs 宣佈,Defiance Daily 2X Space ETF (SPCL) 暫時停止於 Cboe BZX Exchange, Inc. 進行交易

邁阿密, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs 作為主題與槓桿型交易所買賣基金 (ETF) 領導先鋒,今天宣佈 Defiance Daily 2X Space ETF (Cboe BZX: SPCL) 的股份已被 Cboe BZX Exchange, Inc.(「交易所」)暫時停止買賣。

ディファイアンスETFs、シーボーBZX取引所におけるディファイアンス・デイリー2XスペースETF (SPCL) の一時取引停止を発表

マイアミ発, June 14, 2026 (GLOBE NEWSWIRE) -- テーマ型およびレバレッジ型上場投資信託 (ETF) のリーダーであるディファイアンスETFs (Defiance ETFs) は本日、ディファイアンス・デイリー2XスペースETF (Defiance Daily 2X Space ETF) (Cboe BZX: SPCL) の取引が、シーボーBZX取引所 (Cboe BZX Exchange, Inc.) (以下「同取引所」) により一時停止されたことを発表した。

Defiance ETFs Umumkan Penggantungan Sementara Dagangan Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.

MIAMI, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa dagangan saham Defiance Daily 2X Space ETF (Cboe BZX: SPCL) telah digantung buat sementara waktu oleh Cboe BZX Exchange, Inc. (“Bursa”).

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExchange